title: The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
abstract: Given the controversy about the comparative efficacy of first- compared with second-generation antipsychotics in the treatment of schizophrenia, more large-scale evidence is needed to guide clinicians in their prescriptions. Most randomized controlled trials (RCTs) were conducted in centers of excellence on highly selected samples, poorly representative of real-world patients, and often suffered conflicts of interest as they were sponsored by drug companies. The primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine and aripiprazole in a representative sample of schizophrenia patients. The GiSAS trial is an open-label, independent, pragmatic RCT in Italian community-based public psychiatric services. At least 260 patients meeting the DSM-IV criteria for schizophrenia will be randomly allocated to one of the study drugs and followed up for one year. A two-year observational phase will follow. The primary outcome for tolerability will be the onset of metabolic syndrome. The primary endpoint for effectiveness will be discontinuation of antipsychotic monotherapy. Secondary measures include global functioning, time to discontinuation due to side-effects, change of lipid profile, extrapyramidal symptoms and other adverse effects. In the last four years, the GiSAS study group has been working to implement this multicenter RCT. The trial mechanism is now fully functional and working. As of end of February 2011, 260 subjects were randomized by 54 study investigators in 33 out of 43 participating centers.
authors.affiliation: Epidemiology and Social Psychiatry Unit, Mario Negri Institute for Pharmacological Research, Via La Masa 19, 20156 Milan, Italy. alberto.parabiaghi@marionegri.it
authors.forename: Alberto
authors.initials: A
authors.lastname: Parabiaghi
authors.forename: Barbara
authors.initials: B
authors.lastname: D'Avanzo
authors.forename: Mauro
authors.initials: M
authors.lastname: Tettamanti
authors.forename: Angelo
authors.initials: A
authors.lastname: Barbato
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use*; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D007558:Italy; D016015:Logistic Models; D000077152:Olanzapine; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D015363:Quinolones / Q000627:therapeutic use*; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D006220:Haloperidol; D000077152:Olanzapine